Lixte Biotech Holdings Inc. (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships
LIXT is advancing its lead candidate LB-100, a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments The…